Of Chickens and Men: Avian Influenza in Humans

被引:42
作者
Michaelis, Martin [1 ]
Doerr, Hans Wilhelm [1 ]
Cinatl, Jindrich, Jr. [1 ]
机构
[1] Klinikum Johann Wolfgang Goethe Univ, Inst Med Virol, D-60596 Frankfurt, Germany
关键词
RANDOMIZED CONTROLLED-TRIAL; A H5N1 INFECTION; LOWER RESPIRATORY-TRACT; HUMAN AIRWAY EPITHELIUM; SURFACTANT PROTEIN-D; VIRUS NS1 PROTEIN; NEURAMINIDASE INHIBITOR OSELTAMIVIR; ANTIVIRAL CYTOKINE RESPONSES; RECEPTOR-BINDING PROPERTIES; HUMAN NEUTROPHIL DEFENSINS;
D O I
10.2174/156652409787581565
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Highly pathogenic H5N1 avian influenza virus can infect humans and is currently the most deadly influenza virus that has crossed the species barrier. As of December 2007, the spread of H5N1 virus from human to human has been rare. Nobody can predict if H5N1 may cause a pandemic. However, the number of human cases is continuously increasing and changes in virulence and epidemiology have been detected. There are specific pathogenic features of H5N1 infection. In contrast to human-adapted influenza A strains, H5N1 preferentially infects cells of the lower respiratory tract and may spread to tissues outside the respiratory tract in humans. Moreover, H5N1 replication is prolonged in target organs and results in higher viral loads and increased tissue damage. These features will have to be considered for therapeutic protocols for H5N1 infection in humans. Rapid genetic and antigenic changes observed in H5N1 virus isolates represent a challenge for the development of vaccines. In the present review, current knowledge about epidemiology, virulence factors and pathology of H5N1 infections in humans are summarised and discussed. Moreover, the possible roles of anti-influenza drugs in the pandemic situation as well as the development of effective vaccines are subject of this overview.
引用
收藏
页码:131 / 151
页数:21
相关论文
共 241 条
[1]  
*2 WHO CONS CLIN A, 2008, ENGL J MED, V358, P261
[2]   Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations [J].
Abed, Y ;
Goyette, N ;
Boivin, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :556-559
[3]   An overview of the epidemiology of avian influenza [J].
Alexander, Dennis J. .
VACCINE, 2007, 25 (30) :5637-5644
[4]   Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs [J].
Alymova, IV ;
Kodihalli, S ;
Govorkova, EA ;
Fanget, B ;
Gerdil, C ;
Webster, RG .
JOURNAL OF VIROLOGY, 1998, 72 (05) :4472-4477
[5]  
[Anonymous], 2006, Wkly Epidemiol Rec, V81, P328
[6]   Early administration of oral oseltamivir increases the benefits of influenza treatment [J].
Aoki, FY ;
Macleod, MD ;
Paggiaro, P ;
Carewicz, O ;
El Sawy, A ;
Wat, C ;
Griffiths, M ;
Waalberg, E ;
Ward, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :123-129
[7]   How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency [J].
Bhatia, Ajay ;
Kast, Richard E. .
CELLULAR & MOLECULAR BIOLOGY LETTERS, 2007, 12 (01) :111-119
[8]  
Blanton L., 2007, Morbidity and Mortality Weekly Report, V56, P1001
[9]   Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].
Bresson, Jean-Louis ;
Perronne, Christian ;
Launay, Odile ;
Gerdil, Catherine ;
Saville, Melanie ;
Wood, John ;
Hoeschler, Katja ;
Zambon, Maria C. .
LANCET, 2006, 367 (9523) :1657-1664
[10]   Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998 [J].
Bridges, CB ;
Lim, W ;
Hu-Primmer, J ;
Sims, L ;
Fukuda, K ;
Mak, KH ;
Rowe, T ;
Thompson, WW ;
Conn, L ;
Lu, XH ;
Cox, NJ ;
Katz, JM .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (08) :1005-1010